Zhejiang Cheng Yi Pharmaceutical603811.SHValuation Analysis

As of Oct 19, 2026, Zhejiang Cheng Yi Pharmaceutical (603811.SH) trades at a P/E of 17.30x, P/B of 2.17x, P/S of 3.56x, and a dividend yield of 3.20%.
Longitudinal percentile comparison: P/E sits at the 19th percentile over the trailing 10Y window (vs. 54th percentile over 3Y); P/B sits at the 10th percentile over the trailing 10Y window (vs. 30th percentile over 3Y); P/S sits at the 7th percentile over the trailing 10Y window (vs. 16th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 14th percentile within its industry and the 19th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 3.50%, ranking at the 92nd percentile over the trailing 20Y window.
The P/E and P/B long-window percentiles differ by only 9.3 points, pointing to a consistent valuation read across both metrics. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Breaking down the total shareholder yield: 3.20% comes from cash dividends, with an implied ~0.30% from buybacks — a fairly balanced mix of both channels. Zhejiang Cheng Yi Pharmaceutical operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.